PI3K Inhibitors with Isoform-Selective Structures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional therapeutic agents to treat proliferative disorders or diseases mediated by phosphatidylinositol 3-kinase (PI3K) activity, as existing solutions are inadequate.
Innovation Solution
Development of novel compounds with specific structures that act as selective inhibitors of PI3K isoforms, including those with the formula (J) and (I), which can be used in pharmaceutical compositions to treat diseases mediated by PI3K activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PI3K inhibitors are used, then PI3K activity is inhibited, but the inhibitors are not selective enough and have inadequate therapeutic efficacy
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular structures (formulae I and J) that target particular PI3K isoforms (such as PI3Kδ) with high selectivity. The compounds contain specific substituents and structural features that confer isoform-specific binding affinity, allowing differential inhibition of various PI3K isoforms rather than non-selective inhibition.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the inhibitor compounds, including substituent types, positions, and stereochemical configurations. This allows optimization of binding affinity and selectivity for specific PI3K isoforms, transforming general PI3K inhibition into isoform-specific inhibition with improved therapeutic efficacy.
2Adaptability or versatility
If additional therapeutic agents are developed, then treatment options for proliferative disorders increase, but the complexity of compound structures increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor compounds into distinct structural series (formula I and formula J) with specific substituent patterns. This systematic classification allows manageable development and optimization of compounds while maintaining high selectivity and efficacy, reducing the perceived complexity through organized structural design.
Solution Approach 2:
The patent applies universality by creating a framework of compound formulae that can be adapted for multiple therapeutic indications. The core structural motifs in formulae I and J can be modified to target different PI3K isoforms and treat various proliferative disorders (cancer, autoimmune diseases, inflammatory conditions), providing multi-functionality without proportionally increasing structural complexity.
Data Source
AI summary
The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R1, R2, R3 R4, R5, R6 and R7 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more ΡI3Κ isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.